FindTrial
Sign In

Vortioxetine (Lu AA21004)

DRUG13 trials

Sponsors

H. Lundbeck A/S, Takeda

Conditions

DepressionDepressive Disorder, MajorMajor Depressive Disorder

Phase 1

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls
CompletedNCT01607125
H. Lundbeck A/SDepression
Start: 2012-07-31Updated: 2013-09-25

Phase 2

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
CompletedNCT00761306
H. Lundbeck A/SMajor Depressive Disorder
Start: 2007-06-30End: 2008-10-31Updated: 2014-01-29
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
CompletedNCT00839423
H. Lundbeck A/SMajor Depressive Disorder
Start: 2006-08-31End: 2007-09-30Updated: 2014-05-13
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
CompletedNCT01564862
TakedaDepressive Disorder, Major
Start: 2012-04-30End: 2014-02-28Updated: 2015-02-05

Phase 3

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
CompletedNCT00596817
H. Lundbeck A/SMajor Depressive Disorder
Start: 2007-12-31End: 2009-10-31Updated: 2014-03-31
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
CompletedNCT00635219
H. Lundbeck A/SMajor Depressive Disorder
Start: 2008-02-29End: 2009-04-30Updated: 2014-02-11
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
CompletedNCT00694304
H. Lundbeck A/SMajor Depressive Disorder
Start: 2008-05-31End: 2010-04-30Updated: 2014-04-01
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
CompletedNCT00811252
H. Lundbeck A/SMajor Depressive Disorder
Start: 2009-01-31End: 2010-03-31Updated: 2014-01-29
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
CompletedNCT01140906
H. Lundbeck A/SMajor Depressive Disorder
Start: 2010-05-31Updated: 2014-02-11
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
CompletedNCT01323478
H. Lundbeck A/SMajor Depressive Disorder
Start: 2011-04-30End: 2012-10-31Updated: 2014-02-11
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
CompletedNCT01422213
H. Lundbeck A/SMajor Depressive Disorder
Start: 2011-12-31Updated: 2014-08-05
A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
CompletedNCT01488071
H. Lundbeck A/SMajor Depressive Disorder
Start: 2012-01-31Updated: 2014-03-26
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
CompletedNCT01571453
H. Lundbeck A/SMajor Depressive Disorder
Start: 2012-05-31Updated: 2014-10-13

Related Papers

Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
2023-03-0814 citations
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
2023-01-2616 citations
Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder
Current Medical Research and Opinion2020-01-288 citations
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
Advances in Therapy2019-09-2410 citations
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis
Current Medical Research and Opinion2019-08-1710 citations
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment
The Journal of Clinical Psychiatry2019-05-0724 citations
Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.
2018-12-0833 citations
Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings
Journal of Affective Disorders2018-11-059 citations
A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
The International Journal of Neuropsychopharmacology2018-03-103 citations
Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response
Journal of Psychiatric Research2018-02-2225 citations
Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders
Journal of Affective Disorders2017-11-1644 citations
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
The Journal of Clinical Psychiatry2016-10-2496 citations
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
2015-02-1937 citations
Vortioxetine Improves Cognitive Function, Lessens Symptoms of Major Depression
MD Conference Express2014-06-01
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
2012-09-1746 citations